Wall Street Zen Begins Coverage on Regulus Therapeutics (NASDAQ:RGLS)

Research analysts at Wall Street Zen assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) in a report released on Sunday. The firm set a "sell" rating on the biopharmaceutical company's stock.

Several other research firms have also recently weighed in on RGLS. Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partnrs cut Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 target price on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Jones Trading reaffirmed a "hold" rating and set a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $8.50.

Regulus Therapeutics Price Performance

NASDAQ RGLS traded down $0.02 on Friday, hitting $7.89. 1,814,371 shares of the company were exchanged, compared to its average volume of 899,963. The company's 50 day moving average price is $3.93 and its 200-day moving average price is $2.28. The firm has a market capitalization of $546.26 million, a P/E ratio of -7.37 and a beta of 0.49. Regulus Therapeutics has a twelve month low of $0.83 and a twelve month high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.14. As a group, equities analysts expect that Regulus Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

Several large investors have recently made changes to their positions in RGLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Regulus Therapeutics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 1,644 shares in the last quarter. PEAK6 LLC bought a new stake in shares of Regulus Therapeutics in the 4th quarter valued at approximately $95,000. Oppenheimer & Co. Inc. bought a new stake in shares of Regulus Therapeutics in the 1st quarter valued at approximately $96,000. Velan Capital Investment Management LP bought a new stake in shares of Regulus Therapeutics in the 4th quarter valued at approximately $111,000. Finally, AQR Capital Management LLC bought a new stake in shares of Regulus Therapeutics in the 1st quarter valued at approximately $120,000. Institutional investors own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.